Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 4/20 | 0.43 |
| ▸ | WNT3A | P56704 | 4/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 5/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | EPM2A | O95278 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
| ▸ | CDC14A | Q9UNH5 | 1/20 | 0.38 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13750531 | 0.80 | FFAR1 (0.58) | CTNNB1WNT3AHTR1BFFAR1FFAR4 | |
| Oxalic Acid SCHEMBL3812294 | 0.79 | KDM4E (0.42) | CTNNB1WNT3AMRGPRX4HTR1B | |
| SCHEMBL10508698 | 0.78 | KCNA3 (0.43) | CTNNB1WNT3AMRGPRX4HTR1B | |
| SCHEMBL12344285 | 0.78 | CYP2A6 (0.45) | CTNNB1WNT3AMRGPRX4HTR1BEPM2A | |
| SCHEMBL16569016 | 0.78 | CYP1A2 (0.58) | CTNNB1WNT3AMRGPRX4HTR1BFFAR1 | |
| Oxalic Acid SCHEMBL3817410 | 0.77 | SIGMAR1 (0.42) | CTNNB1WNT3AHTR1B | |
| SCHEMBL47967 | 0.77 | SLC5A1 (0.36) | SLC5A1SLC5A2 | |
| SCHEMBL103859 | 0.77 | GAA (0.53) | CTNNB1WNT3AMRGPRX4HTR1BEPM2A | |
| SCHEMBL4588706 | 0.76 | CYP1A2 (0.59) | FFAR1FFAR4 | |
| SCHEMBL48011 | 0.76 | NPC1 (0.38) | SLC5A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43676-E1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-RE43676-E1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-RE43676-E1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8129535-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129535-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129535-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8067406-B2 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20110112066-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| US-7897594-B2 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20100075941-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| US-7468443-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| US-7468443-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| US-7468443-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| EP-1437353-B1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-20060205709-A1 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-09-14 | — | — | US | disclosed |
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| US-7087594-B2 | central nervous system disorders; regenerating nervous systems | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| EP-1614419-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-01-11 | — | — | EP | disclosed |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1437353-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205709-A1 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | RB1, ALDH1A2, NR2E3 | CTNNB1 2053/4885WNT3A 2711/4885MRGPRX4 392/4885 |
| US-20110112066-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | RB1, ALDH1A2, NR2E3 | CTNNB1 2053/4885WNT3A 2711/4885MRGPRX4 392/4885 |
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | CTNNB1 1823/4885WNT3A 3942/4885MRGPRX4 2392/4885 |
| US-20100075941-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | RB1, ALDH1A2, NR2E3 | CTNNB1 2053/4885WNT3A 2711/4885MRGPRX4 392/4885 |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | CTNNB1 1823/4885WNT3A 3942/4885MRGPRX4 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.